Close Menu

NEW YORK (360Dx) – A new European consortium plans to remake the way in vitro diagnostics are developed and used in treating infectious diseases in a bid to combat antimicrobial resistance.

The effort, called VALUE-Dx, commenced its activities this month with a kickoff meeting held in Madrid. Backed by the European Commission, the Wellcome Trust, and private companies, VALUE-Dx will run for four years with a total budget of €14 million ($15.8 million).

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.